Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Estimation of absolute risk for prostate cancer using genetic markers and family history
The Prostate, 06/30/09
Xu J et al. - In a study to assess whether multiple DNA sequence variants in the form of single-nucleotide polymorphisms (SNPs) are associated with prostate cancer (PCa) risk, it was reported that this risk prediction model may be used to identify men at considerably elevated PCa risk who may be selected for chemoprevention.
Methods- Absolute risk for PCa among men with various numbers of inherited risk alleles and family history of PCa was estimated in a population-based case-control study (2893 cases and 1781 controls) and a nested case-control study in the US (1172 cases and 1157 controls).
- Increased number of risk alleles and positive family history were independently associated with PCa risk.
- Considering men with 11 risk alleles (mode) and negative family history as having baseline risk, men who had ≥14 risk alleles and positive family history had an odds ratio (OR) of 4.92 in the Swedish study.
- These associations were confirmed in the US population.
- Once a man's SNP genotypes and family history are known, his absolute risk for PCa can be readily calculated and easily interpreted.
- For example, 55-year-old men with a family history and ≥14 risk alleles have a 52% and 41% risk of being diagnosed with PCa in the next 20 yrs in the Swedish and US populations, respectively.
- In comparison, without knowledge of genotype and family history, these men had an average population absolute risk of 13%.
Related Articles
CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa
Urologic Oncology: Seminars and Original Investigations, 10/27/09
Relevance Score: 67%
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Relevance Score: 67%
Genetic Effects on Postprandial Variations of Inflammatory Markers in Healthy Individuals
Obesity, 11/18/09
Relevance Score: 66%
Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping
Malaria Journal, 11/02/09
Relevance Score: 66%
Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling
Cancer Science, 10/28/09
Relevance Score: 66%
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09
Article Search
Sponsor


See Latest Articles


